• PDF / 169,591 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 21 Downloads / 207 Views

DOWNLOAD

REPORT

0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868

1

Recommend Documents

Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis

147 62 6MB

Hereditary transthyretin amyloidosis overview

150 37 448KB

Amyloidosis Diagnosis and Treatment

170 43 4MB

Mifepristone plus misoprostol less costly than misoprostol alone

162 23 182KB

Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective the

153 85 1MB

Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas

146 103 2MB

Tetraparesis and sensorimotor axonal polyneuropathy due to co-occurrence of Pompe disease and hereditary ATTR amyloidosi

140 61 173KB

Cardiomyopathy and autonomic neuropathy in hereditary amyloidosis: Defining the cart and the horse

149 44 304KB

Single-tablet ART as effective, less costly than multiple-tablet ART

138 65 163KB

Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy

151 15 1MB

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement

178 21 1MB

Cardiac Amyloidosis

170 60 24MB